The myocardial infarction (MI) therapeutics market will register a CAGR of almost 3% by 2023

LONDON, Feb. 11, 2019 /PRNewswire/ — About this market MI along with other cardiovascular problems, is the leading cause of premature deaths in the world. The rising incidence of...

LONDON, Feb. 11, 2019 /PRNewswire/ — About this market

MI along with other cardiovascular problems, is the leading cause of premature deaths in the world. The rising incidence of coronary artery disease, obesity, diabetes, and hypertension, along with a sedentary lifestyle, smoking, and reduced physical activities, is expected to increase the risk factors for cardiovascular diseases including MI. Apart from these factors, the rapid rise in the geriatric population is increasing the incidence of MI. Hence, the incidence of MI is expected to increase with the rapidly expanding geriatric population. The rising incidence of MI will propel the growth of the market during the forecast period. Technavio’s analysts have predicted that the myocardial infarction (MI) therapeutics market will register a CAGR of almost 3% by 2023.

Download the full report: https://www.reportbuyer.com/product/5734241

Market Overview

Increased adoption of novel antithrombotics

Novel antithrombotics such as NOACs and antiplatelet drugs (BRILINTA and Effient) possess the potential to expand the scope of the treatment for MI. These drugs offer significant advantages such as target specificity. The market also contains specific antidotes for these drugs. which can help prevent life-threatening or uncontrolled bleeding.

Extensive use of generics

A generic drug is a medication that is the same as the existing approved branded drug in terms of dosage form, safety, strength, route of administration, quality, and performance characteristics. Generic drugs are allowed for sale after the expiry of the patent of the original branded drug. Thus, generic drugs have comparatively lower prices than the branded drugs.

For the detailed list of factors that will drive and challenge the growth of the myocardial infarction (MI) therapeutics market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately concentrated and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

Download the full report: https://www.reportbuyer.com/product/5734241

About Reportbuyer

Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith

Research Advisor at Reportbuyer.com

Email: sarah@reportbuyer.com

Tel: +1 (718) 213 4904

Website: www.reportbuyer.com

SOURCE ReportBuyer

Related Links

http://www.reportbuyer.com

Categories
Uncategorized
No Comment

Leave a Reply

*

*

RELATED BY